PRNewswire

PARIS, June 3, 2024 /PRNewswire/ -- A spectacular, never-before-seen 30-minute experience will open on the Champs-Élysées on 7 June 2024.

The Théâtre du Lido offers visitors an immersive multi-sensory attraction every day from 11am to 8pm, engulfing them in an artistic vision inspired by the revisited and enhanced music of Vivaldi's Four Seasons.

With climate change, the four distinct seasons are becoming increasingly uncertain. With the help of artificial... (continue reading...)

NORCROSS, Ga., June 3, 2024 /PRNewswire/ -- Hi-Tech Pharmaceuticals has increased its capacity on Precision Protein™, which is arguably the best protein on the market!  Precision Protein™ (100% Hydrolyzed Whey Protein comes with a never-before-seen enzyme known as Embedded Enzyme Technology™ or EET™, which completely changes the way protein behaves in your body. It works by seeking out specific points in the long amino acid chains that make up the protein... (continue reading...)

NEW YORK and MEXICO CITY, June 3, 2024 /PRNewswire/ -- Bloomberg SEF LLC today announced that the first electronically traded TIIE de Fondeo ("F-TIIE") swap transaction was executed on its CFTC-registered swap execution facility, BSEF. Mexico-based Banco Invex and Finamex Casa de Bolsa traded a 3-month swap on BSEF using request-for-quote (RFQ) trading protocol. The trade was cleared by CME Clearing. Mexican derivatives markets seek to replace their usage of the... (continue reading...)

TAIPEI, June 3, 2024 /PRNewswire/ -- Doing a keynote before the Computex starts and during the evening at Taiwan's top university stadium is something nobody had ever tried before. However, according to the latest report from DIGITIMES Asia, a technology-focused media, Nvidia CEO Jansen Huang is determined to flex his muscles to steal the spotlight from competitors by announcing a new platform and AI PC wins ahead of the big event.

Despite the heavy rain, National... (continue reading...)

-       Long-term efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those receiving prior venetoclax-       Data from a subgroup analyses of elderly R/R mIDH1 AML patients treated with olutasidenib shows consistent CR/CRh results-       Overview of the Phase 1b trial of R289 in patients with lower-risk MDS

SOUTH SAN FRANCISCO, Calif., June 3, 2024... (continue reading...)